Related Experiment Video

Updated: Feb 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Molecular targets and targeted therapeutics in endometrial cancer

Britta Weigelt1, Susana Banerjee

  • 1Cancer Research UK London Research Institute, London, UK.

Current Opinion in Oncology
|May 15, 2012
PubMed
Abstract

Insights

This review covers molecular changes in endometrial cancer, a common gynecological malignancy. Understanding these alterations is key to developing new treatments like mTOR inhibitors and antiangiogenic agents.

Area of Science:

  • Gynecological Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Endometrial cancer is the most frequent gynecological malignancy in Western countries.
  • Two main subtypes exist: type I (endometrioid) and type II (non-endometrioid) carcinomas.
  • Understanding the molecular basis of endometrial cancer is crucial for advancing treatment strategies.

Purpose of the Study:

  • To review the molecular alterations identified in endometrial cancer.
  • To discuss how this molecular knowledge informs the development of novel therapeutic approaches.
  • To highlight the importance of considering tumor heterogeneity in future clinical trials.

Main Methods:

  • This is a review article, synthesizing existing research on endometrial cancer molecular alterations.
  • Literature search focused on molecular targets and their clinical trial outcomes.
  • Analysis of data from clinical trials investigating targeted agents.

Main Results:

  • Molecularly targeted agents are now being evaluated in clinical trials for endometrial cancer.
  • Mechanistic target of rapamycin (mTOR) inhibitors and antiangiogenic agents show promise.
  • Further targeted approaches are under investigation, building on initial findings.

Conclusions:

  • The molecular and clinicopathological heterogeneity of endometrial cancer must guide future clinical trial design.
  • Incorporating robust biomarkers is essential for the success of therapeutic strategies.
  • Personalized treatment approaches tailored to specific molecular profiles are likely to improve outcomes.

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.7K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
18
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
17
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K